Zobrazeno 1 - 10
of 206
pro vyhledávání: '"HARRIET L. ROBINSON"'
Autor:
Kelly E. Seaton, Aaron Deal, Xue Han, Shuying S. Li, Ashley Clayton, Jack Heptinstall, Ann Duerr, Mary A. Allen, Xiaoying Shen, Sheetal Sawant, Nicole L. Yates, Paul Spearman, Gavin Churchyard, Paul A. Goepfert, Janine Maenza, Glenda Gray, Giuseppe Pantaleo, Laura Polakowski, Harriet L. Robinson, Shannon Grant, April K. Randhawa, Ying Huang, Cecilia Morgan, Nicole Grunenberg, Shelly Karuna, Peter B. Gilbert, M. Juliana McElrath, Yunda Huang, Georgia D. Tomaras, NIAID HIV Vaccine Trials Network (HVTN) 076, 088, 086, 096, 097, 205 Study Teams
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Abstract We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone
Externí odkaz:
https://doaj.org/article/2f212191b8044471a09de9b169fd03d0
Autor:
Harriet L. Robinson, Andrea Marzi
Publikováno v:
Expert Review of Vaccines, Vol 17, Iss 9, Pp 769-771 (2018)
Externí odkaz:
https://doaj.org/article/4c2558e925e34fca9a13ba1c4d23d797
Autor:
Susan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, Kelly E Seaton, Guido Ferrari, M Anthony Moody, Nicole Frahm, David C Montefiori, Christine M Hay, Paul A Goepfert, Lindsey R Baden, Harriet L Robinson, Xuesong Yu, Peter B Gilbert, M Juliana McElrath, Yunda Huang, Georgia D Tomaras, HIV Vaccine Trials Network (HVTN) 094 Study Group
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0179597 (2017)
BACKGROUNDA phase 1 trial of a clade B HIV vaccine in HIV-uninfected adults evaluated the safety and immunogenicity of a DNA prime co-expressing GM-CSF (Dg) followed by different numbers and intervals of modified vaccinia Ankara Boosts (M). Both vacc
Externí odkaz:
https://doaj.org/article/300820dc06284fec8a11c5a6cc8671e2
Autor:
Nathanael P McCurley, Arban Domi, Rahul Basu, Kevin O Saunders, Celia C LaBranche, David C Montefiori, Barton F Haynes, Harriet L Robinson
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0177863 (2017)
Here we report the construction, antigenicity and initial immunogenicity testing of DNA and modified vaccinia Ankara (MVA) vaccines expressing virus-like particles (VLPs) displaying sequential clade C Envelopes (Envs) that co-evolved with the elicita
Externí odkaz:
https://doaj.org/article/6fae7210e0a14cf5a4ad716965710975
Autor:
Melanie Thompson, Sonya L Heath, Bentley Sweeton, Kathy Williams, Pamela Cunningham, Brandon F Keele, Sharon Sen, Brent E Palmer, Nicolas Chomont, Yongxian Xu, Rahul Basu, Michael S Hellerstein, Suefen Kwa, Harriet L Robinson
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0163164 (2016)
GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA) boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral treatment (ART) to evaluate safety and vaccine-elicited T cell responses, and
Externí odkaz:
https://doaj.org/article/5cc4cb023f42458891f15ee42796989d
Autor:
M. Juliana McElrath, Jack Heptinstall, Xiaoying Shen, Cecilia Morgan, Shuying S. Li, Harriet L. Robinson, Giuseppe Pantaleo, Shelly Karuna, Nicole L. Yates, Shannon Grant, Nicole Grunenberg, Glenda Gray, Peter B. Gilbert, Ashley Clayton, Laura Polakowski, April K. Randhawa, Sheetal Sawant, Mary Allen, Xue Han, Ying Huang, Janine Maenza, Kelly E. Seaton, Paul Spearman, Ann Duerr, Yunda Huang, Aaron Deal, Gavin J. Churchyard, Georgia D. Tomaras, Paul A. Goepfert
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
NPJ Vaccines
NPJ Vaccines
We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone. We meas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025e014366d2586e9f16eed6c18c0ff4
https://doi.org/10.1038/s41541-021-00305-8
https://doi.org/10.1038/s41541-021-00305-8
Autor:
Maurine D. Miner, Lindsey R. Baden, Colleen F. Kelley, M. Juliana McElrath, Martin Casapia, Kelly E. Seaton, Georgia D. Tomaras, Paul A. Goepfert, Susan Buchbinder, Janine Maenza, Michael C. Keefer, Magdalena E. Sobieszczyk, Javier R. Lama, Stephen C. De Rosa, Faruk Sinangil, Carter Lee, Harriet L. Robinson, David C. Montefiori, Vineeta Gulati, Marnie Elizaga, Carmen Paez, Chenchen Yu, Kristen W. Cohen, Laura Polakowski, Yunda Huang
Publikováno v:
Vaccine
Background Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest period in participants previousl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb1f11b109ac04abb578782749b0f1d9
https://pubmed.ncbi.nlm.nih.gov/34229888
https://pubmed.ncbi.nlm.nih.gov/34229888
Autor:
Fatima Laher, James J. Kobie, Juilee Thakar, Michael S. Piepenbrink, Harriet L. Robinson, Glenda Gray, Susan Buchbinder, Michael C. Keefer, Yunda Huang, Kelly E. Seaton, John Hural, Gavin J. Churchyard, Georgia D. Tomaras, Holly Janes, Paul A. Goepfert, Rohith Palli
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-15 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-15 (2020)
Efficacious HIV-1 vaccination requires elicitation of long-lived antibody responses. However, our understanding of how different vaccine types elicit durable antibody responses is lacking. To assess the impact of vaccine type on antibody responses, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83d89d1b7a96fe1de7cdc04b8552a25
http://europepmc.org/articles/PMC7398916
http://europepmc.org/articles/PMC7398916
Autor:
Harriet L. Robinson
Publikováno v:
Clinical Pharmacology and Therapeutics
Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40-year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf3b22b89ef0e277574f6c4b2fe1930
http://europepmc.org/articles/PMC6282490
http://europepmc.org/articles/PMC6282490
Publikováno v:
Human Gene Therapy
DNA vaccines were pioneered by several groups in the early 1990s. This article presents the reflections of one of these groups on their work with retroviral vectors in chickens that contributed to the discovery and early development of DNA vaccines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82bad858eaf22facceacf28c01dc193d
https://doi.org/10.1089/hum.2018.066
https://doi.org/10.1089/hum.2018.066